The estimated Net Worth of Joseph M Mandato is at least $3.09 Million dollars as of 21 November 2018. Joseph Mandato owns over 100,000 units of Axogen stock worth over $1,660,000 and over the last 12 years Joseph sold AXGN stock worth over $1,430,738.
Joseph has made over 8 trades of the Axogen stock since 2014, according to the Form 4 filled with the SEC. Most recently Joseph bought 100,000 units of AXGN stock worth $39,000 on 21 November 2018.
The largest trade Joseph's ever made was selling 149,618 units of Axogen stock on 8 August 2016 worth over $1,277,738. On average, Joseph trades about 19,478 units every 85 days since 2013. As of 21 November 2018 Joseph still owns at least 125,000 units of Axogen stock.
You can see the complete history of Joseph Mandato stock trades at the bottom of the page.
Joseph's mailing address filed with the SEC is 750 US-202 #100, Bridgewater, NJ 08807, USA.
Over the last 13 years, insiders at Axogen have traded over $73,805,978 worth of Axogen stock and bought 504,297 units worth $3,119,117 . The most active insiders traders include James E Deerfield Mgmt L.P...., Guido J Neels, and Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of $455,132. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth $158,085.
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
Axogen executives and other stock owners filed with the SEC include: